Sequent Scientific Ltd. logo

Sequent Scientific Ltd. (SEQUENT)

Delisted
29 Jan 2026
XNSE XNSE
202. 40
-1.59
-0.7794%
57.53B Market Cap
- P/E Ratio
- Div Yield
13,647 Volume
0 Eps
203.99
Previous Close
Day Range
201.43 207.8
Year Range
117.35 257.85
Want to track SEQUENT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

SEQUENT Chart

Sequent Scientific Ltd. (SEQUENT) FAQ

What does "Delisted" mean?

Sequent Scientific Ltd. has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

No dividend payments were recorded prior to delisting.

How long did the company pay dividends?

The company did not have a dividend payment history.

Were there any stock splits?

The last recorded stock split occurred on Feb 25, 2016 with a ratio of 10:2.

What was the last known trading price?

The stock last traded at ₹202.40 on Jan 29, 2026 before being delisted.

Sequent Scientific Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Rajaram Narayanan CEO
XNSE Exchange
Y7670U126 CUSIP
IN Country
1,244 Employees
8 Sep 2021 Last Dividend
25 Feb 2016 Last Split
- IPO Date

Overview

Sequent Scientific Limited is a global player in the animal health industry, offering a wide array of products and services across several key areas. With a history dating back to 1985, the company has established a strong presence in the market and specializes in the development and manufacturing of animal health active pharmaceutical ingredients (APIs), along with a range of formulations. These offerings cater to a variety of needs, including anthelmintics, anti-protozoal treatments, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology products. Originally known as PI Drugs and Pharmaceuticals Limited, the company has transformed over the years to focus on animal health, supported by its expertise in analytical solutions. Headquartered in Mumbai, India, Sequent Scientific Limited operates as a subsidiary of CA Harbor Investments, marking its significance in the global market through comprehensive solutions in animal health care.

Products and Services

  • Animal Health Active Pharmaceutical Ingredients (APIs)

    Sequent Scientific Limited specializes in offering a comprehensive range of animal health APIs, focusing on the development and manufacture of critical components used in various animal health products. These APIs cover numerous therapeutic areas, such as anti-parasitics, anti-inflammatories, and anti-infectives, ensuring high-quality ingredients for effective animal health solutions.

  • Formulations

    The company provides a variety of formulations in the animal health sector, including treatments for endo and ecto parasites, anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives, and dermatological products. These formulations are developed to meet the diverse needs of the animal health industry, offering effective treatments and preventive measures for various animal health issues.

  • Anthelmintics (Endo and Ecto Parasiticides)

    Specializing in the area of parasitic control, Sequent offers both endo and ecto parasiticides as part of its product portfolio. These products are designed to tackle a wide range of parasitic infections, helping to maintain the health and well-being of animals by preventing and treating parasitic infestations.

  • Anti-protozoal Products

    With a focus on combating protozoal infections, the company develops and provides anti-protozoal products. These are critical in the treatment and prevention of diseases caused by protozoan parasites, ensuring healthier lives for animals affected by such conditions.

  • Nutraceuticals

    Understanding the importance of nutrition in animal health, Sequent offers a range of nutraceutical products. These include supplements and functional foods designed to provide health benefits beyond the basic nutritional value found in traditional food sources, aiding in the overall well-being and performance of animals.

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

    The company's portfolio also includes nonsteroidal anti-inflammatory drugs (NSAIDs), which are essential for managing pain and inflammation in animals. These products play a crucial role in veterinary care, providing relief and enhancing the quality of life for animals suffering from various conditions.

  • Anti-infectives

    Sequent manufactures and supplies a wide range of anti-infective products, aimed at preventing and treating infections in animals. These products are vital in controlling bacterial, viral, and fungal infections, ensuring the health and safety of animal populations.

  • Dermatology

    A key area of focus for Sequent is dermatology, with a range of products designed to address various skin conditions in animals. From treatments for common skin infections to solutions for more complex dermatological issues, the company provides effective options for maintaining healthy skin in animals.

  • Analytical Solutions

    Beyond its primary focus on animal health products, Sequent also provides comprehensive analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations. This includes services like method validation, stability testing, and microbiology for APIs and finished products, ensuring the highest standards of quality and safety in all offerings.

Contact Information

Address: Srivallis Corporate, Hyderabad, India, 500033
Phone: 91 22 4111 4777